Drug Profile
Research programme: cardiovascular disease therapy - SEQUENOM
Latest Information Update: 04 Apr 2008
Price :
$50
*
At a glance
- Originator SEQUENOM
- Class Peptides; Small molecules
- Mechanism of Action Genetic transcription modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 29 Jul 2004 SEQUENOM has terminated its drug discovery efforts
- 08 Oct 2001 Gemini Genomics has been acquired by SEQUENOM
- 30 Mar 2001 This programme is available for licensing (http://www.sequenom.com)